Galecto (GLTO) Competitors

Galecto (NASDAQ:GLTO) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.

Which has more volatility and risk, GLTO or RNXT?

Galecto has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, RenovoRx has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Do analysts rate GLTO or RNXT?

Galecto currently has a consensus target price of $7.60, suggesting a potential upside of 988.83%. RenovoRx has a consensus target price of $13.00, suggesting a potential upside of 900.00%. Given Galecto's higher probable upside, analysts clearly believe Galecto is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galecto	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
RenovoRx	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do institutionals and insiders believe in GLTO or RNXT?

29.4% of Galecto shares are held by institutional investors. Comparatively, 2.3% of RenovoRx shares are held by institutional investors. 12.1% of Galecto shares are held by insiders. Comparatively, 9.0% of RenovoRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media favor GLTO or RNXT?

In the previous week, Galecto had 2 more articles in the media than RenovoRx. MarketBeat recorded 4 mentions for Galecto and 2 mentions for RenovoRx. RenovoRx's average media sentiment score of 1.44 beat Galecto's score of 0.64 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Overall Sentiment
Galecto	Positive
RenovoRx	Positive

Is GLTO or RNXT more profitable?

Galecto's return on equity of -90.21% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galecto	N/A	-90.21%	-73.98%
RenovoRx	N/A	-210.91%	-144.42%

Which has higher earnings and valuation, GLTO or RNXT?

RenovoRx is trading at a lower price-to-earnings ratio than Galecto, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galecto	N/A	N/A	-$61.62M	-$2.01	-0.35
RenovoRx	N/A	N/A	-$9.89M	-$1.05	-1.24

Does the MarketBeat Community believe in GLTO or RNXT?

Galecto received 25 more outperform votes than RenovoRx when rated by MarketBeat users. Likewise, 60.00% of users gave Galecto an outperform vote while only 35.71% of users gave RenovoRx an outperform vote.

Company	Underperform	Outperform
Galecto	Outperform Votes 30 60.00%	Underperform Votes 20 40.00%
RenovoRx	Outperform Votes 5 35.71%	Underperform Votes 9 64.29%

Summary

Galecto beats RenovoRx on 11 of the 15 factors compared between the two stocks.